Palmetto Peptides Complete Guide to the Research Peptide Sermorelin
Research Use Only Disclaimer: Sermorelin is sold by Palmetto Peptides strictly for in vitro and preclinical laboratory research purposes. It is not approved for human or veterinary therapeutic use, is not a dietary supplement, and is not intended for self-research application or consumption. All information on this page is intended for licensed researchers and scientific professionals. Users are responsible for compliance with all applicable local, state, and federal regulations governing research peptides.
Palmetto Peptides Complete Guide to the Research Peptide Sermorelin
Direct answer: Sermorelin — formally designated GHRH (1-29) NH2 — is a synthetic 29-amino acid analog of endogenous growth hormone-releasing hormone (GHRH). It binds selectively to the GHRH receptor (GHRHR) on anterior pituitary somatotroph cells and stimulates growth hormone (GH) secretion through a cAMP-mediated intracellular signaling cascade. In preclinical research, Sermorelin is the most widely referenced short-acting GHRH analog used to study pituitary somatotroph biology, pulsatile GH dynamics, GH axis pharmacology, and downstream IGF-1 signaling in rodent and in vitro models.
This guide covers everything a researcher needs to understand Sermorelin as a laboratory tool: its structure, mechanism, pharmacokinetics, in vitro and animal model research findings, comparisons with related analogs, purity standards, handling protocols, and procurement guidance.
What Is Sermorelin? An Overview for Researchers
Sermorelin represents the biologically active N-terminal fragment of human GHRH. Native GHRH is a 44-amino acid hypothalamic peptide that travels through the hypothalamic-pituitary portal system to stimulate GH release from the anterior pituitary. Structure-activity relationship studies conducted in the early 1980s — following the landmark 1982 isolation of GHRH from pancreatic tumor tissue by Guillemin and Rivier — established that the first 29 amino acids (with a C-terminal amide) retain full agonist activity at the GHRHR. This truncated fragment became Sermorelin.
Because it mirrors the mechanism of endogenous GHRH rather than delivering exogenous GH directly, Sermorelin produces GH secretion within the normal feedback architecture of the pituitary-hypothalamic axis. This makes it a particularly valuable tool for researchers who want to study physiologically relevant GH release patterns rather than pharmacological GH flooding.
In plain terms: The hypothalamus normally sends a signal (GHRH) to tell the pituitary to release growth hormone. Sermorelin is a shorter version of that signal that works the same way. Researchers use it to study how this communication system works at the molecular, cellular, and whole-organism level.
Key Identifiers
| Property | Value |
|---|---|
| IUPAC Name | GHRH (1-29) NH2 |
| CAS Number | 86168-78-7 |
| Molecular Weight | ~3,357 Da |
| Amino Acid Length | 29 |
| C-terminus | Amide (-NH2) |
| Supplied Form | Lyophilized acetate salt |
| Primary Receptor | GHRHR (Class B GPCR) |
| Storage (lyophilized) | -20°C, protected from light |
Table 1: Key identifiers for Sermorelin research peptide.
The Science of Sermorelin: Mechanism of Action
The GHRH Receptor
Sermorelin's pharmacological target is the growth hormone-releasing hormone receptor (GHRHR), a class B G protein-coupled receptor (GPCR) expressed predominantly on somatotroph cells of the anterior pituitary. GHRHR is encoded by the GHRHR gene and belongs to the secretin receptor family. Roughly 40-50% of anterior pituitary cells are somatotrophs, and essentially all of these express functional GHRHR.
The Signaling Cascade: Step by Step
When Sermorelin binds GHRHR, the following intracellular events unfold:
Step 1 — Gs protein activation: The receptor undergoes a conformational change that activates the coupled Gs alpha subunit, which then stimulates adenylyl cyclase.
Step 2 — cAMP production: Adenylyl cyclase converts ATP to cyclic AMP (cAMP), which accumulates intracellularly within 2-5 minutes of Sermorelin exposure.
Step 3 — PKA and CREB activation: Elevated cAMP activates protein kinase A (PKA), which phosphorylates the transcription factor CREB (cAMP response element-binding protein). CREB activation drives transcription of the GH gene (GH1), increasing GH synthesis.
Step 4 — Calcium influx and GH exocytosis: Concurrent with cAMP signaling, GHRHR activation opens voltage-gated calcium channels. The resulting rise in intracellular Ca²⁺ triggers exocytosis of GH-containing secretory granules into the bloodstream (in vivo) or conditioned media (in vitro).
Figure 1: Simplified signaling cascade from Sermorelin-GHRHR binding to GH secretion.
Somatostatin: The Counterbalance
GH secretion is naturally oscillatory because the stimulatory GHRH signal is opposed by somatostatin (SST), a hypothalamic inhibitory peptide. Somatostatin inhibits somatotroph function through its own receptor family (SSTRs), suppressing cAMP accumulation and GH release. Sermorelin-based research designs frequently exploit this biology by co-administering or withholding somatostatin analogs to modulate the observed GH response.
For an in-depth mechanistic breakdown including receptor desensitization dynamics, see our article on Sermorelin mechanism of action in pituitary cell and in vitro studies.
Sermorelin's Chemical Structure and the Acetate Salt Form
The Amino Acid Sequence
Sermorelin's full sequence is:
Three structural features drive its pharmacology:
- N-terminal tyrosine (position 1): Essential for GHRHR binding. Removal or modification dramatically reduces receptor affinity.
- Helical middle segment (residues 6-13): Adopts an alpha-helical conformation that engages a hydrophobic groove on the GHRHR extracellular domain.
- C-terminal amide (-NH2): Enhances receptor binding affinity and protects against carboxypeptidase degradation compared to the free acid form.
Why Acetate Salt?
Research-grade Sermorelin is supplied as the acetate salt because acetate counterions improve aqueous solubility, storage stability during lyophilization, and compositional reproducibility. The acetate counterions are not covalently bonded to the peptide and dissociate completely in aqueous solution — so once reconstituted, the peptide is pharmacologically identical to the free acid form.
For a complete structural analysis including synthesis methodology, see our article on Sermorelin chemical structure, synthesis, and acetate form.
History: How Sermorelin Was Developed
The story of Sermorelin begins with one of the more unusual events in modern endocrinology — a pancreatic tumor that caused a patient to overproduce growth hormone.
In 1982, Roger Guillemin's team at the Salk Institute isolated a 44-amino acid peptide from a GHRH-secreting pancreatic tumor that was causing acromegaly in its host. The Rivier/Vale group independently characterized a 40-amino acid form from similar tissue in the same year. Both groups published simultaneously, establishing the molecular identity of endogenous GHRH.
Structure-activity studies quickly followed, systematically testing truncated fragments of the new peptide. By 1983-1984, researchers had confirmed that GHRH (1-29) NH2 — the first 29 residues with a C-terminal amide — retained full GHRHR agonist activity. This became the standard research tool now known as Sermorelin.
In 1997, Sermorelin acetate was approved by the FDA as the pharmaceutical product Geref (Serono) for diagnostic assessment of GH secretory capacity in children with suspected GH deficiency. The product was discontinued from the US pharmaceutical market in 2002 for commercial reasons unrelated to safety or efficacy, after which Sermorelin returned to its role as a preclinical and in vitro research peptide.
For the full historical account, see our article on the history and development of Sermorelin as a GHRH 1-29 analog research peptide.
Pharmacokinetics: Half-Life and Plasma Clearance
Sermorelin's most defining pharmacokinetic feature is its extremely short plasma half-life — approximately 2-3 minutes in rodent models and 10-12 minutes in primates. This rapid clearance occurs because Sermorelin is an excellent substrate for dipeptidyl peptidase IV (DPP-IV), a ubiquitous plasma serine protease that cleaves peptides at the second amino acid from the N-terminus when that position is an alanine or proline. Sermorelin's Ala-2 position makes it immediately susceptible.
Additional endopeptidases including neutral endopeptidase (neprilysin) and chymotrypsin-like proteases contribute to clearance across multiple cleavage sites simultaneously.
Despite the 2-3 minute half-life, Sermorelin produces a GH response that peaks at 5-20 minutes and takes 30-60 minutes to return to baseline. This pharmacokinetic-pharmacodynamic disconnect occurs because downstream intracellular signaling — cAMP accumulation, PKA activity, GH vesicle mobilization — continues for a period after receptor occupancy ends.
| PK Parameter | Sermorelin | CJC-1295 (no DAC) | CJC-1295 (with DAC) |
|---|---|---|---|
| Plasma half-life (rat) | ~2-3 min | ~30 min | ~6-8 days |
| GH peak timing | 5-20 min | 15-30 min | Extended |
| GH duration per concentration | ~30-60 min | ~60-90 min | Days |
| DPP-IV susceptibility | High | Low | Low |
Table 2: Sermorelin pharmacokinetics vs. related GHRH analogs.
The rapid clearance makes Sermorelin ideal for studying acute, pulsatile GH dynamics — each concentration produces a brief GH pulse that closely mimics the natural oscillatory GH secretion pattern in rodents. It also means that GHRHR desensitization from rapid repeat concentration is a real variable researchers must account for in protocol design.
For full PK data including absorption by route, volume of distribution, and concentration interval implications, see our article on Sermorelin pharmacokinetics and half-life in preclinical lab models.
In Vitro Research: What Cell Studies Show
GH Secretion Concentration-Response in Somatotroph Cultures
In primary dispersed anterior pituitary cells from rats — the gold standard in vitro model for GHRHR research — Sermorelin stimulates GH release in a clean sigmoidal concentration-response relationship:
- EC10 (10% of maximal response): ~0.1 nM
- EC50 (50% of maximal response): ~1-5 nM
- Emax (maximal response): Achieved at ~10-100 nM, producing 3-10 fold GH increase over basal
GH secretion peaks in conditioned media within 15-30 minutes of Sermorelin addition and returns toward baseline by 60 minutes as receptor desensitization and peptide degradation occur. Established cell lines including GH3 and MtT/S show qualitatively similar concentration-response relationships with quantitative differences that reflect altered receptor expression versus primary cultures.
IGF-1: The Downstream Biomarker
IGF-1 is not produced by pituitary cells — it is synthesized primarily in hepatocytes in response to GH receptor signaling. Measuring Sermorelin's effect on IGF-1 therefore requires animal model studies, not pituitary cell cultures alone. In rodent models, a single Sermorelin concentration does not reliably alter circulating IGF-1. Repeated daily concentration over one to four weeks produces progressive IGF-1 elevation, with the magnitude proportional to concentration and baseline GH status of the animals.
For a full synthesis of in vitro findings and preclinical IGF-1 research, see our article on Sermorelin in vitro and preclinical insights on GH secretion and IGF-1 in research models.
Animal Model Research: Pulsatile GH Secretion
Rodent Models: The Backbone of Sermorelin Preclinical Literature
Rats — particularly male Sprague-Dawley — are the primary preclinical model for Sermorelin GH research. Their structured, rhythmic GH pulse pattern (pulses every 3-4 hours in males) makes them ideal for studying how Sermorelin modulates pulse amplitude and frequency.
Consistent findings across rodent studies:
- Sermorelin produces concentration-dependent GH pulses with peaks at 5-20 minutes post-research application
- The peptide primarily increases GH pulse amplitude rather than pulse frequency
- GHRHR desensitization occurs with rapid repeat concentration but is reversible with adequate rest intervals (3-4 hours or more)
- Male and female rats show different baseline GH secretory patterns, and Sermorelin responses reflect these sex differences
- Aged rodents show attenuated but present GH responses, consistent with age-related somatopause biology
The lit/lit Mouse: Confirming Receptor Specificity
The little (lit/lit) mouse carries a loss-of-function point mutation in the Ghrhr gene. These animals show no GH response to Sermorelin — a critical negative control that has been used repeatedly across decades of GHRH research to confirm that Sermorelin's GH-stimulating effects are mediated exclusively through GHRHR.
For the full preclinical literature review, see our article on animal model research findings on Sermorelin and pulsatile GH secretion.
Sermorelin in the Context of the Broader GH Research Field
The Somatopause and Aging Research
One of the most active areas of Sermorelin research involves aged animal models. Age-related GH decline (the "somatopause") is characterized in rodents by reduced GH pulse amplitude, decreased GHRHR expression, increased somatostatin tone, and reduced hypothalamic GHRH output. Sermorelin is used both as a diagnostic challenge (measuring residual GH secretory capacity) and as an experimental tool (testing whether pulsatile GHRHR stimulation can partially restore GH dynamics) in aged animal cohorts.
GHRHR Pharmacology and Antagonist Research
Sermorelin serves as the standard reference agonist in GHRHR pharmacology studies. Any researcher developing or evaluating GHRHR antagonists — for applications in cancer biology research, metabolic research, or basic receptor pharmacology — uses Sermorelin to establish the baseline agonist GH response that antagonist candidates must displace or inhibit.
Neuroendocrinology: Hypothalamic-Pituitary Interaction
Sermorelin is used in neuroendocrinology research to study how the hypothalamic-pituitary feedback loop responds to variables like fasting, sleep deprivation, sex hormone status, and circadian time. Its specificity for GHRHR makes it a clean pharmacological probe for isolating the GHRH arm of GH regulation from other regulators.
For a comprehensive overview of research domains, see our article on preclinical research applications of Sermorelin in endocrinology and GH axis laboratory studies.
Comparing Sermorelin to Related GHRH Analogs
A researcher choosing between GHRH analogs must think clearly about what question they are asking. The analogs differ in duration of action, structural modifications, and the research context for which each is best suited.
Sermorelin vs. CJC-1295
CJC-1295 is also built on the GHRH 1-29 framework but incorporates amino acid substitutions (CJC-1295 without DAC, a.k.a. Modified GRF 1-29) or an albumin-binding Drug Affinity Complex (CJC-1295 with DAC) that extends plasma half-life from Sermorelin's 2-3 minutes to 30 minutes or 6-8 days respectively.
Choose Sermorelin when studying acute, pulsatile GH dynamics.
Choose CJC-1295 no DAC when an intermediate duration is needed.
Choose CJC-1295 with DAC when studying chronic, sustained GH elevation models.
See our full analysis: Sermorelin vs CJC-1295: comparative analysis for growth hormone secretagogue research.
Sermorelin vs. Ipamorelin
Ipamorelin is not a GHRH analog at all — it is a ghrelin mimetic that activates the GHS-R1a receptor through an entirely independent signaling pathway (Gq/phospholipase C/calcium, rather than Gs/cAMP). Despite this mechanistic difference, both produce GH secretion from somatotrophs.
The research value of combining Sermorelin and Ipamorelin is that their two pathways are additive, allowing researchers to study synergistic GH stimulation or to isolate individual pathway contributions with receptor-specific antagonists.
See the full comparison: Sermorelin vs Ipamorelin: key differences in research peptide GH pathway studies.
Sermorelin vs. Tesamorelin
Tesamorelin is based on GHRH (1-40) with an N-terminal trans-3-hexenoic acid modification that blocks DPP-IV cleavage and extends plasma half-life to approximately 30-40 minutes. Unlike Sermorelin, Tesamorelin has an FDA-approved pharmaceutical form (Egrifta) for a specific metabolic indication, giving it a more developed clinical data context.
Choose Sermorelin when pulsatile dynamics, historical comparability, or DPP-IV sensitivity is the variable of interest.
Choose Tesamorelin when intermediate half-life or metabolic axis research context is relevant.
See the comparison: Tesamorelin vs Sermorelin: comparative research on GHRH analogs in animal studies.
Summary Comparison Table
| Feature | Sermorelin | CJC-1295 (DAC) | Ipamorelin | Tesamorelin |
|---|---|---|---|---|
| Receptor | GHRHR | GHRHR | GHS-R1a | GHRHR |
| Mechanism | Gs/cAMP | Gs/cAMP | Gq/PKC/Ca²⁺ | Gs/cAMP |
| Half-life (rat) | ~2-3 min | ~6-8 days | ~2 hours | ~30-40 min |
| GH Pattern | Pulsatile | Sustained | Moderate | Moderate |
| DPP-IV | Susceptible | Resistant | N/A | Resistant |
| FDA status | Research | Research | Research | Approved (specific indication) |
Table 3: Sermorelin vs. major GH secretagogue research analogs.
Purity, Quality Standards, and What to Look For
Experimental validity begins with reagent quality. For Sermorelin, that means verifying that the peptide you are adding to your assay is actually Sermorelin — at the concentration you think it is — and not a mixture of truncated sequences, oxidized variants, or other impurities that would introduce confounds.
The Research-Grade Standard
High-quality research-grade Sermorelin should meet all of the following:
98%+ HPLC purity (per lot): Confirmed by reverse-phase HPLC, reported as percent of total peak area. This is not a brand-level average — it should be lot-specific.
Mass spectrometry (MS) identity confirmation: Confirms the molecular weight of the main HPLC peak matches the theoretical Sermorelin mass (~3,357 Da ± 1 Da).
Lot-specific Certificate of Analysis (CoA): Documents peptide identity, lot number, HPLC purity, MS result, appearance, net weight, storage conditions, and testing date. Every order, every lot.
Endotoxin testing (LAL assay): Essential for any in vivo application. Research-grade peptides for animal studies should show endotoxin below 2.0 EU/mg.
Third-party testing: Independent laboratory verification eliminates manufacturer conflict of interest and provides the highest quality assurance level.
For a full quality evaluation guide, see our article on purity testing, quality standards, and third-party analysis for Sermorelin research peptides.
Laboratory Protocols: Reconstituting and Storing Sermorelin
Proper handling of Sermorelin in the laboratory is as important as the experimental design itself. Errors in reconstitution or storage introduce concentration variability, peptide degradation, and contamination that can invalidate results.
Reconstitution Summary
| Step | Action |
|---|---|
| 1 | Calculate target concentration: mg peptide ÷ mL solvent = mg/mL |
| 2 | Allow vial to reach room temperature; swab stopper with alcohol |
| 3 | Draw correct volume of bacteriostatic water into syringe |
| 4 | apply solvent slowly along the vial wall — not directly onto the cake |
| 5 | Swirl gently; do not vortex or shake |
| 6 | Inspect for clarity; label with concentration, date, and lot number |
Table 4: Sermorelin reconstitution protocol summary.
Preferred solvent: Bacteriostatic water (0.9% benzyl alcohol) — provides a 28-day stability window under refrigeration. Sterile saline is acceptable but limits shelf life to 24 hours.
Storage Guidelines
- Lyophilized (unopened): -20°C, protected from light, up to 24 months
- Reconstituted with bacteriostatic water: 2-8°C (refrigerator), up to 28 days
- Reconstituted, long-term: Aliquot into single-use volumes; freeze at -20°C; avoid repeat freeze-thaw cycles
For the complete step-by-step protocol with concentration calculation tables and solvent compatibility guide, see our article on how to reconstitute and store Sermorelin acetate for laboratory research.
Preclinical Research Applications: Where Sermorelin Fits
Sermorelin sees use across multiple research domains within endocrinology and GH axis biology:
Somatotroph cell biology: In vitro GHRHR signaling studies, cAMP and calcium assays, receptor desensitization and internalization research.
GH deficiency models: Stimulation challenge assays in GH-deficient rodents; distinguishing hypothalamic from pituitary-origin GH deficiency.
Somatopause and aging research: Quantifying GH secretory reserve in aged animals; testing whether pulsatile GHRHR stimulation restores GH dynamics.
GH-IGF-1 metabolic axis: Controlled GH pulse generation for studying hepatic IGF-1 responses and downstream metabolic marker changes in animal models.
GHRHR pharmacology: Reference agonist for antagonist development, competitive inhibition studies, and receptor characterization.
Neuroendocrinology: Hypothalamic-pituitary interaction, sex hormone modulation of GH axis, circadian GH rhythm studies.
For a full research application map with guidance on model selection, see our article on preclinical research applications of Sermorelin in endocrinology and GH axis laboratory studies.
The History of Sermorelin: From Nobel-Adjacent Discovery to Research Standard
The path to Sermorelin traces back to a Nobel Prize-winning lineage. Roger Guillemin and Andrew Schally won the 1977 Nobel Prize in Physiology or Medicine for isolating hypothalamic releasing factors — but the GH-releasing factor they had suspected for decades remained elusive until 1982, when tumors provided what the hypothalamus couldn't yield in sufficient quantity.
The 1982 isolation of GHRH from pancreatic tumor tissue — independently confirmed by two Salk Institute groups publishing within months of each other — was the breakthrough that made Sermorelin possible. Structure-activity studies over the following two years established GHRH (1-29) NH2 as the minimal biologically active fragment, and Sermorelin became the standardized synthetic research tool used across endocrinology labs worldwide.
This scientific heritage means Sermorelin benefits from decades of preclinical literature — a rare advantage for a research peptide that allows researchers to place their data in a well-established scientific context.
See the complete account in our article on the history and development of Sermorelin as a GHRH 1-29 analog research peptide.
Frequently Asked Questions
What is Sermorelin and what is it used for in research?
Sermorelin (GHRH 1-29 NH2) is a synthetic 29-amino acid GHRH analog used in preclinical and in vitro research to study GH axis biology. It binds GHRHR on anterior pituitary somatotrophs and stimulates GH secretion via cAMP signaling. Research applications span somatotroph cell biology, GH deficiency models, pulsatile GH dynamics, aging research, and GHRHR pharmacology.
How does Sermorelin stimulate GH secretion?
GHRHR binding activates Gs protein → adenylyl cyclase → cAMP → PKA → CREB → GH gene transcription. Simultaneously, calcium channel opening triggers exocytosis of GH secretory granules. Both GH synthesis and immediate release are stimulated.
What is Sermorelin's half-life in research models?
Approximately 2-3 minutes in rodents and 10-12 minutes in primates. DPP-IV cleavage at Ala-2 is the primary clearance mechanism. Despite rapid plasma clearance, GH peaks at 5-20 minutes and takes 30-60 minutes to return to baseline.
How is Sermorelin different from CJC-1295?
Same receptor (GHRHR), but very different half-lives. Sermorelin: ~2-3 min (pulsatile). CJC-1295 no DAC: ~30 min. CJC-1295 with DAC: ~6-8 days (sustained). Choose based on research question.
What purity should research-grade Sermorelin have?
98%+ HPLC purity per lot, MS identity confirmed, lot-specific CoA. For in vivo use: LAL endotoxin below 2.0 EU/mg.
How do you reconstitute Sermorelin?
apply bacteriostatic water along the vial wall, swirl gently, do not vortex. Standard 1 mg/mL. Store at 2-8°C for 28 days or aliquot and freeze at -20°C.
Is Sermorelin legal to purchase?
Yes, for licensed researchers conducting legitimate laboratory research. Not a controlled substance. Not for human or veterinary use.
What animal models are used?
Primarily rats (male Sprague-Dawley). Also mice, including lit/lit GHRHR-null as a negative control. Some NHP studies exist.
Where to Buy Sermorelin Research Peptide
Palmetto Peptides supplies research-grade Sermorelin acetate meeting the quality standards described in this guide: 98%+ HPLC purity per lot, MS identity confirmation, lot-specific CoA, and LAL endotoxin testing. Lyophilized for maximum stability in transit and storage.
View Sermorelin Research Peptide at Palmetto Peptides
Related peptides frequently used alongside Sermorelin in GH axis research:
- CJC-1295 Research Peptide — extended half-life GHRH analog for sustained GH studies
- Ipamorelin Research Peptide — GHS-R1a agonist; complementary GH secretagogue pathway
- Tesamorelin Research Peptide — GHRH (1-40) analog with N-terminal modification
- IGF-1 LR3 Research Peptide — downstream GH axis effector peptide
For supplier evaluation guidance, see our article on where to buy high-purity Sermorelin research peptide: quality and supplier guide.
Supporting Articles in This Research Cluster
This pillar page is supported by a full cluster of focused articles covering each aspect of Sermorelin research in depth. Use them to go deeper on the topic most relevant to your work:
Table 5: Sermorelin research cluster supporting articles.
Summary
Sermorelin (GHRH 1-29 NH2) is a well-characterized, receptor-specific GHRH analog with decades of preclinical literature supporting its use as a GH axis research tool. Its key properties as a research peptide are:
- High receptor specificity: Acts exclusively at GHRHR with no known off-target receptor activity at research-relevant concentrations
- Physiologically relevant mechanism: Activates GH secretion through the same cAMP-mediated pathway as endogenous GHRH
- Short half-life: ~2-3 minutes in rodents — ideal for pulsatile GH dynamics research; limits duration studies
- Deep preclinical literature: Decades of published rodent and primate data provide strong reference context for new experiments
- Defined quality standards: 98%+ HPLC purity, MS confirmation, lot-specific CoA — the benchmarks that distinguish research-grade from substandard material
- Well-established lab protocols: Reconstitution in bacteriostatic water, refrigerated storage up to 28 days, freeze-thaw aliquotting for longer-term use
For researchers studying the GH axis — whether at the level of receptor signaling, whole-animal GH pulsatility, downstream IGF-1 dynamics, or comparative GHRH pharmacology — Sermorelin remains the foundational tool against which newer analogs are characterized and compared.
References
- Guillemin R, et al. "Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly." Science. 1982;218(4572):585-587.
- Rivier J, et al. "Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour." Nature. 1982;300(5889):276-278.
- Mayo KE. "Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone." Molecular Endocrinology. 1992;6(10):1734-1744.
- Frohman LA, et al. "Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma." Journal of Clinical Investigation. 1989;83(5):1533-1540.
- Frohman LA, Jansson JO. "Growth hormone-releasing hormone." Endocrine Reviews. 1986;7(3):223-253.
- Tannenbaum GS, Ling N. "The interrelationship of growth hormone-releasing factor and somatostatin in generation of the ultradian rhythm of GH secretion." Endocrinology. 1984;115(5):1952-1957.
- Walker RF. "Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?" Clinical Interventions in Aging. 2006;1(4):307-308.
- Veldhuis JD, Bowers CY. "Integrating GHS within the concept of a physiological hormonal axis." Reviews in Endocrine and Metabolic Disorders. 2010;11(1):57-69.
Palmetto Peptides Research Team
Palmetto Peptides supplies research-grade peptides for licensed laboratory use only. Nothing on this site constitutes medical advice, a treatment recommendation, or an endorsement of any therapeutic use. Sermorelin is for research purposes only.
Researchers studying growth hormone secretagogues can explore Sermorelin research peptide, Ipamorelin research compound, CJC-1295 no-DAC research peptide along with related peptide compounds at Palmetto Peptides.
Sermorelin Research Article Index
- Sermorelin Mechanism of Action Pituitary Research
- Sermorelin vs Cjc 1295 Research Comparison
- Sermorelin Animal Model Research Pulsatile Gh
- Reconstitute Store Sermorelin Acetate Lab
- Sermorelin Chemical Structure Acetate Synthesis
- Sermorelin vs Ipamorelin Research Comparison
- Sermorelin History Development Ghrh 1 29
- Sermorelin Purity Testing Quality Standards
- Sermorelin Preclinical Research Applications Endocrinology
- Sermorelin Pharmacokinetics Half Life Preclinical
- Tesamorelin vs Sermorelin Ghrh Analog Comparison
- Buy Sermorelin Research Peptide Supplier Guide
- Sermorelin in Vitro Studies Gh Igf1 Research Models